YolTech Therapeutics CEO Yuxuan Wu (L) and chief technology officer Zi Jun Emma Wang

September 10, 2025 09:39 AM EDTUpdated September 15, 05:26 PM

Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study

Ryan Cross

Senior Science Correspondent

YolTech Therapeutics, a prolific Chinese biotech that’s already begun testing four CRISPR gene editing therapies in small clinical studies, raised a $44.5 million Series B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRENDING NOW

Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

FDA brings GSK's Blenrep back to the market in multiple myeloma

Are recent strides in neurology R&D enough to make it a hot M&A target?

Novo Nordisk lines up corporate affairs exec, overshadowed by board drama

Sanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts vaccine franchise

Post-Hoc: Why we tracked pharma’s private jet flights to DC

The advent of digital therapeutics and what it means for healthcare

Ex­clu­sive: Chi­nese CRISPR com­pa­ny YolTech rais­es $45M as it plans for first Phase 3 study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

FDA brings GSK's Blenrep back to the mar­ket in mul­ti­ple myelo­ma

Are re­cent strides in neu­rol­o­gy R&D enough to make it a hot M&A tar­get?

No­vo Nordisk lines up cor­po­rate af­fairs ex­ec, over­shad­owed by board dra­ma

Sanofi’s Dupix­ent sales con­tin­ue to de­liv­er as ‘neg­a­tive buzz’ im­pacts vac­cine fran­chise

Post-Hoc: Why we tracked phar­ma’s pri­vate jet flights to DC

The ad­vent of dig­i­tal ther­a­peu­tics and what it means for health­care

Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study

FDA brings GSK's Blenrep back to the market in multiple myeloma

Are recent strides in neurology R&D enough to make it a hot M&A target?

Novo Nordisk lines up corporate affairs exec, overshadowed by board drama

Sanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts vaccine franchise

Post-Hoc: Why we tracked pharma’s private jet flights to DC

The advent of digital therapeutics and what it means for healthcare